Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.date.accessioned | 2023-07-31T16:31:11Z | - |
dc.date.available | 2023-07-31T16:31:11Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 2072-6694 | * |
dc.identifier.other | OAK-33549 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265316 | - |
dc.description.abstract | Purpose: This study aimed to determine the risk factors for palbociclib-induced grade 4 or grade 3 neutropenia (NP) requiring dose reduction or delayed treatment in patients with HR+/HER2−metastatic breast cancer in the first 3 cycles (early grade 3/4 NP) and whether the early developing grade 3/4 NP affects progression-free survival. Methods: A retrospective study using electronic medical records was conducted on patients who received palbociclib for metastatic breast cancer between January 2018 and August 2022. The early grade 3/4 NP risk factors were evaluated with univariate and multivariable logistic regression analyses. In addition, the Kaplan-Meier method was used to estimate the median progression-free survival (PFS) to analyze the effect of early grade 3/4 NP on treatment. Results: Out of the 264 patients included in this study, 173 (65.6%) experienced early grade 3/4 NP. A total of four models were applied for multivariable analysis to identify early grade 3/4 NP-developing factors. Low baseline ANC, WBC, PLT, and BSA were significant risk factors for early grade 3/4 NP; baseline ANC < 3700/mm3, WBC < 6.30 × 109/mm3, PLT < 230 × 109/mm3, and BSA < 1.58 m2 increased the risk by approximately 4.0-fold, 3.7–4.0-fold, 2.1-fold, and 2.0-fold, respectively. Early grade 3/4 NP did not affect PFS (p = 0.710), although patients with early grade 3/4 NP had more frequent dose reductions or treatment delays. Conclusions: Based on the results, low baseline ANC, WBC, PLT, and BSA were associated with early grade 3/4 NP. Patients with risk factors require careful monitoring, and this study is expected to help predict NP, which may appear in early treatment. © 2023 by the authors. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | CDK4/6 inhibitor | * |
dc.subject | metastatic breast cancer | * |
dc.subject | neutropenia | * |
dc.subject | palbociclib | * |
dc.title | Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer | * |
dc.type | Article | * |
dc.relation.issue | 10 | * |
dc.relation.volume | 15 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Cancers | * |
dc.identifier.doi | 10.3390/cancers15102810 | * |
dc.identifier.wosid | WOS:000997061900001 | * |
dc.identifier.scopusid | 2-s2.0-85160733649 | * |
dc.author.google | Lee Y. | * |
dc.author.google | Lee D. | * |
dc.author.google | Seo I. | * |
dc.author.google | Chae H. | * |
dc.author.google | Sim S.H. | * |
dc.author.google | Lee K.S. | * |
dc.author.google | Gwak H.S. | * |
dc.date.modifydate | 20240422115307 | * |